drug
S-531011
Phase 2updated 3mo agoby $SGIOF SHIONOGI & CO LTD
Phase 2community read0 votes
indications
indications
NSCLCMelanoma
all catalysts(0)
nothing on the calendar yet
Trials studying S-531011
- phase2A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of Concurrent Combination Therapy of S-531011 Plus Fruquintinib or S-531011 Plus Fruquintinib Plus Pembrolizumab in Patients With MSS/pMMR Colorectal Cancer
- phase2S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 31m ago
Found something off?
comments(0)
5-min edit window · permanent after that